We recently compiled a list of the Jim Cramer Shed Light on These 8 Stocks Recently. In this article, we are going to take a ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

By Christy Santhosh and Puyaan Singh (Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its ...

Truist raised the firm’s price target on AbbVie (ABBV) to $217 from $211 and keeps a Buy rating on the shares after its Q4 results. The ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

Shares of AbbVie ( ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...